title: Signaling pathways induced by lipoproteins derived from Mycoplasma salivarium and a synthetic lipopeptide (FSL-1) in normal human gingival fibroblasts.
abstract: Lipoproteins derived from Mycoplasma salivarium and a synthetic lipopeptide (FSL-1) activate human gingival fibroblasts to induce IL-6 production and ICAM-1 expression. Human gingival fibroblasts were treated with lipoproteins or FSL-1 and then examined for the activation of mitogen-activated protein kinases (MAPKs), ERK1/2, p38, and SAPK/JNK, and transcription factors, AP-1 and NF-kappaB. Western blotting indicated that p38 and SAPK/JNK were activated in response to the stimulators, but the activation of ERK1/2 could not be discriminated because ERK1/2 was activated in the absence of stimulators. The p38 inhibitor SB 203580 also suppressed their IL-6 production-inducing activities, whereas the ERK1/2-activating MAPK kinase (MEK1) inhibitor PD 98059 did not suppress their activities. Moreover, they were capable of inducing the activation of AP-1 and NF-KB. NF-kappaB activation was also confirmed by the phosphorylation of IkappaB-alpha. On the basis of these results, it was concluded that lipoproteins of M. salivarium and FSL-1 are capable of activating the MAPKs p38 and SAPK/JNK and the transcriptional factors AP-1 and NF-kappaB in human gingival fibroblasts.
authors: Department of Oral Pathobiological Science, Hokkaido University Graduate School of Dental Medicine, Sapporo, Japan.
authors: Jun-ichiro
authors: J
authors: Nakamura
authors: Ken-ichiro
authors: K
authors: Shibata
authors: Akira
authors: A
authors: Hasebe
authors: Takeshi
authors: T
authors: Into
authors: Tsuguo
authors: T
authors: Watanabe
authors: Noboru
authors: N
authors: Ohata
mesh_terms: D001426:Bacterial Proteins / Q000276:immunology*; D015153:Blotting, Western / Q000379:methods; D004075:Diglycerides / Q000276:immunology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology; D005419:Flavonoids / Q000494:pharmacology; D005881:Gingiva / Q000166:cytology / Q000276:immunology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D015850:Interleukin-6 / Q000096:biosynthesis; D008074:Lipoproteins / Q000276:immunology*; D009174:Mycoplasma / Q000276:immunology*; D016328:NF-kappa B / Q000276:immunology; D009842:Oligopeptides / Q000276:immunology*; D010766:Phosphorylation; D011725:Pyridines / Q000494:pharmacology; D015398:Signal Transduction / Q000276:immunology*; D018808:Transcription Factor AP-1 / Q000276:immunology
chemical_list: D001426:Bacterial Proteins; D004075:Diglycerides; D004791:Enzyme Inhibitors; C460864:FSL-1 lipoprotein, synthetic; D005419:Flavonoids; D007093:Imidazoles; D015850:Interleukin-6; D008074:Lipoproteins; D016328:NF-kappa B; D009842:Oligopeptides; D011725:Pyridines; D018808:Transcription Factor AP-1; C093642:SB 203580; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one